Enliven Therapeutics Inc Stock Price, News & Analysis

Enliven Therapeutics (ELVN) has reported its Q4 and full year 2024 financial results, highlighting continued progress in its clinical programs. The company maintains a strong financial position with $313.4 million in cash and equivalents, providing runway into mid-2027.

Key pipeline updates include anticipated Phase 1 data for ELVN-001, their BCR::ABL kinase inhibitor for chronic myeloid leukemia (CML), expected mid-2025. Their second program, ELVN-002, a CNS-penetrant HER2 inhibitor, will report both monotherapy and combination trial data in H2 2025.

Financial highlights for FY2024 show R&D expenses of $80.8 million (up from $64.6M in 2023), G&A expenses of $23.8 million (up from $19.0M), and a net loss of $89.0 million (compared to $71.6M in 2023). The company is preparing for a potential pivotal trial of ELVN-001 in 2026.

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics discovery and development, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 10:30 a.m. ET.

The event will be accessible through a live webcast on the company's investor relations website at ir.enliventherapeutics.com. Interested parties who cannot attend the live session can access the archived recording, which will remain available for 90 days after the event's conclusion.

Enliven Therapeutics (ELVN) reported positive Phase 1 trial results for ELVN-001 in CML patients, achieving a 44.4% (8/18) cumulative major molecular response rate by 24 weeks. The drug remained well-tolerated with no dose reductions. The company continues advancing ELVN-002 trials in HER2+ metastatic breast cancer and colorectal cancer. Financial results show $291.8 million in cash and equivalents, providing runway into late 2026. Q3 2024 resulted in a net loss of $23.2 million, with R&D expenses at $21.3 million and G&A expenses at $5.8 million.

Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Jefferies London Healthcare Conference on November 19, 2024, at 9:30 a.m. GMT. The company's management will engage in a fireside chat, which will be webcast live. Interested parties can access the webcast via the investor relations section of Enliven's website. The webcast will remain available for 90 days post-event.

Enliven Therapeutics (Nasdaq: ELVN) has announced details for the presentation of updated ELVN-001 Phase 1a data at the ESH-iCMLf 26th Annual John Goldman Conference on CML. The event will take place from September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML) patients.

The oral presentation, titled "Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML," will be delivered by Dr. Fabian Lang from Goethe University Hospital on September 28, 2024, at 3:35 p.m. CEST. The presentation will be part of Scientific Session 5: New drugs and combinations. Enliven will make the presentation available on their website after the conference.

Enliven Therapeutics (Nasdaq: ELVN) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Dosing of first patients in Phase 1b arm for ELVN-001 in CML and Phase 1a trial for ELVN-002 in HER2+ MBC and CRC.

2. Strong financial position with $312.4 million in cash, providing runway into late 2026.

3. R&D expenses increased to $18.8 million in Q2 2024 from $15.2 million in Q2 2023.

4. Net loss widened to $20.0 million in Q2 2024 from $16.7 million in Q2 2023.

5. Upcoming presentation of updated ELVN-001 Phase 1a data at ESH-iCMLf Conference in September 2024.

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage precision oncology company, has announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference on June 5 at 8:30 a.m. ET and the Goldman Sachs Annual Global Healthcare Conference on June 10 at 3:20 p.m. ET. Both events will feature fireside chats with Enliven's management. The sessions will be webcast live and available on the company's investor relations website, with archives accessible for 30 days post-event.

Enliven Therapeutics announced positive results from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia, showing a 44% major molecular response (MMR) rate by 12 weeks. The company has $321 million in cash, extending its runway to late 2026. A $90 million PIPE financing and board appointment of Lori Kunkel were highlighted. Enliven also advanced its ELVN-002 trial for HER2+ cancers, with the first site activated and patient dosing expected in Q2 2024. Financial results showed increased R&D and G&A expenses, leading to a net loss of $22.7 million for Q1 2024, compared to $14.7 million in Q1 2023.